Recombinant hepatitis b vaccine
Sold as Engerix-b
No structure available
This product's active ingredient could not be matched to a single known compound.
Background
Registration
- Applicants
- 1
- Registrations
- 1
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Glaxosmithkline South Africa (Pty) Limited | Engerix-b | Not stated | U0186 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Engerix-b EACH 1 ml CONTAINS RECOMBINANT HEPATITIS B VACCINE 20 ug | Not listed | U0186U/30.1/186 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Respiratory syncytial virus antigen
Consolidated Schedules 06 July 2026, line 7790
S2: Hepatitis b vaccine
Consolidated Schedules 06 July 2026, line 2071
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.